CStone Pharmaceuticals ( ($HK:2616) ) has shared an announcement. CStone Pharmaceuticals announced its participation in the 2025 European Society ...

- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and ...

Advanced colon cancer is the leading cause of cancer-related death in young American men and the second highest worldwide. In ...

Neoadjuvant immune checkpoint inhibitors significantly increase pathologic response compared with FLOT in patients with ...

Molecular predictors and mechanisms of immune checkpoint inhibitor-induced myocarditis: A case-control study with translational correlates. Predictive factors for cardiac events following concurrent ...

Immune checkpoint inhibitors (ICIs), such as anti-CTLA-4 antibodies, are widely used in cancer immunotherapy. CTLA-4 blockers such as Yervoy (ipilimumab, Bristol Myers Squibb Co.) stimulate ...

26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases Deep and durable responses ...

SAN FRANCISCO and SUZHOU, China, Feb. 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...